Last reviewed · How we verify
GM-CSF and G-CSF
GM-CSF and G-CSF are cytokines that stimulate the proliferation and differentiation of granulocytes and monocytes from bone marrow progenitor cells.
GM-CSF and G-CSF are cytokines that stimulate the proliferation and differentiation of granulocytes and monocytes from bone marrow progenitor cells. Used for Chemotherapy-induced neutropenia, Bone marrow transplantation support, Severe chronic neutropenia.
At a glance
| Generic name | GM-CSF and G-CSF |
|---|---|
| Sponsor | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
| Drug class | Hematopoietic growth factor |
| Target | GM-CSF receptor (CD116) and G-CSF receptor (CD114) |
| Modality | Biologic |
| Therapeutic area | Hematology/Immunology |
| Phase | FDA-approved |
Mechanism of action
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) are hematopoietic growth factors that bind to their respective receptors on myeloid progenitor cells, promoting their expansion, maturation, and functional activation. These cytokines enhance neutrophil and monocyte production, improving immune function and reducing infection risk in immunocompromised patients.
Approved indications
- Chemotherapy-induced neutropenia
- Bone marrow transplantation support
- Severe chronic neutropenia
- Mobilization of peripheral blood progenitor cells
Common side effects
- Bone pain
- Fever
- Fatigue
- Headache
- Injection site reactions
- Splenomegaly
Key clinical trials
- Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse (PHASE1, PHASE2)
- Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PHASE1, PHASE2)
- Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (PHASE1)
- Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia (PHASE2)
- Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (PHASE2)
- Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy (PHASE2)
- Therapy for Children With Advanced Stage Neuroblastoma (PHASE2)
- Auto Stem Cell Transplant for Lymphoma Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GM-CSF and G-CSF CI brief — competitive landscape report
- GM-CSF and G-CSF updates RSS · CI watch RSS
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine portfolio CI